Abbott公司即将研制先兆子痫检测方法

根据一项近期的协议，Abbott实验室获得了将Nephromics公司获得的的检测和监测先兆子痫的两种蛋白质，开发成商业化产品的全球准独家权利。，

Abbott打算开发成为检测先兆子痫的体外检测方法。目前对这种危及生命的疾病还没有特异性的诊断检测方法，这种疾病每年都危及许多妊娠妇女。Abbott实验室诊断测试与系统开发副总裁William Brow博士解释说：“Abbott的目标是开发分娩前检测方法，能够用于对妊娠并发症进行早期的危险分层检测。”

Abbott具有研发内分泌和其它激素相关检测方法的历史；向全球诊断检测市场的关键领域提供范围广泛的革新设备系统和检测方法。

“Because preeclampsia can strike quickly, potentially causing severe and immediate complications such as seizures and organ failure that threaten both the health of the baby and mother unless pregnancy is induced, early diagnostic tests are needed,” observed David Barch, M.D., medical director, Abbott Diagnostics. “These tests would be developed for use on our premier diagnostic analyzer, the Architect integrated immunoassay and clinical chemistry system.”
Abbott诊断公司的医学主任David Barch说：“因为先兆子痫起病迅速，能够导致严重的并发症，例如癫痫发作和器官功能衰竭，在妊娠没有开始之前就会危及婴儿和母亲的健康，因此早期诊断检测是十分必要的。这些即将研制的检测方法，将使用我们公司功能强大的诊断分析仪：Architect综合免疫分析和临床化学系统。”

Abbott to Develop Preeclampsia Test
 
Under a recent agreement, worldwide semi-exclusive rights to commercialize products using patents of Nephromics (Chestnut Hill, MA, USA) related to two proteins for detecting and monitoring preeclampsia have been granted to Abbott Laboratories (Abbott Park, IL, USA).

Abbott intends to develop an in vitro diagnostic test to detect preeclampsia. There is currently no specific diagnostic test for this life-threatening disease that affects many pregnant women each year. “Abbott’s goal is to develop prenatal tests that could be utilized for early risk stratification of pregnancy complications,” explained William Brown, Ph.D., vice president, diagnostic assays and systems development, Abbott Labs.

Abbott has a history of developing endocrine and other hormone-related tests and offers a broad range of innovative instrument systems and tests across key segments of the global diagnostics market. Immunodiagnostics is a core component of the company’s medical products business.

“Because preeclampsia can strike quickly, potentially causing severe and immediate complications such as seizures and organ failure that threaten both the health of the baby and mother unless pregnancy is induced, early diagnostic tests are needed,” observed David Barch, M.D., medical director, Abbott Diagnostics. “These tests would be developed for use on our premier diagnostic analyzer, the Architect integrated immunoassay and clinical chemistry system.”